grade by grade [18:50 mL/minute per 1.73 m 2 . 1 (See Elimination: Special Populations, under Pharmacokinetics.) Not studied in patients with moderate or severe renal impairment (estimated GFR] FEATURED: CAR-T Cell Therapy Overview Mechanism of Action KTE-C19 Studies KTE-C19 Cancer Targets Adverse Events Manufacturing Drug Status Rx Availability Prescription only N/A CSA Schedule Not a controlled drug 1 year Approval History FDA approved 2016 Manufacturer Intercept Pharmaceuticals, Inc. Drug Class Miscellaneous GI agents Related Drugs Biliary Cirrhosis ursodiol , Actigall , obeticholic acid , More... Ocaliva Rating No Reviews - Be the first! No Reviews - Be the first! Not Rated - Be the first! you ought to be
the hundreds Ocaliva remains
EmoticonEmoticon